SCHEMBL240855

SCHEMBL240855

CCCCN1CCN(C)CC1

nearest known ligand 0.52

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
GNAI3 P08754 3/20 0.52
GNAO1 P09471 3/20 0.52
GNAI1 P63096 3/20 0.52
PAOX Q6QHF9 1/20 0.48
SIGMAR1 Q99720 2/20 0.45
GLB1 P16278 1/20 0.43
CSNK2A2 P19784 1/20 0.42
CSNK2B P67870 1/20 0.42
CSNK2A1 P68400 1/20 0.42
CSNK2A3 Q8NEV1 1/20 0.42
DRD2 P14416 1/20 0.42
DRD3 P35462 1/20 0.42
USP2 O75604 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL27751181 0.97 GNAI3 (0.50) GNAI3GNAO1GNAI1PAOXSIGMAR1
Hydrochloric Acid SCHEMBL27751184 0.95 GNAI3 (0.54) GNAI3GNAO1GNAI1PAOXSIGMAR1
SCHEMBL28860188 0.95 GNAI3 (0.48) GNAI3GNAO1GNAI1PAOXSIGMAR1
Dimethylamine SCHEMBL8071368 0.93 GNAI3 (0.47) GNAI3GNAO1GNAI1PAOXSIGMAR1
SCHEMBL23767406 0.92 GNAI3 (0.61) GNAI3GNAO1GNAI1PAOXSIGMAR1
SCHEMBL107589 0.92 GNAI3 (0.61) GNAI3GNAO1GNAI1PAOXSIGMAR1
SCHEMBL18538874 0.91 GNAI3 (0.58) GNAI3GNAO1GNAI1SIGMAR1GLB1
SCHEMBL1537447 0.91
SCHEMBL1043894 0.91 GNAI3 (0.58) GNAI3GNAO1GNAI1SIGMAR1GLB1
SCHEMBL2318272 0.91 GNAI3 (0.58) GNAI3GNAO1GNAI1SIGMAR1GLB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 602 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269737-A1 7-(Piperazine-1-Ymethyl)-1H-Indole-2-Carboxylic Acid (Phenyl)-Amide Derivatives and Allied Compounds as P38 Map Kinase Inhibitors for the Treatment of Respiratory Diseases BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-03 US claimed
EP-1237935-A1 MODIFIED POLYMERS PREPARED WITH LANTHANIDE-BASED CATALYSTS Bridgestone Corporation (JP) 2002-09-11 EP claimed
WO-2001034659-A1 MODIFIED POLYMERS PREPARED WITH LANTHANIDE-BASED CATALYSTS BRIDGESTONE CORPORATION (JP) 2001-05-17 WO claimed
US-20240239804-A1 FUROINDAZOLE DERIVATIVES AS ANTAGONISTS OR INHIBITORS OF GPR84 BAYER AKTIENGESELLSCHAFT (DE) 2024-07-18 US disclosed
US-20240228493-A1 LRRK2 INHIBITORS AND USES THEREOF NEURON23, INC. 2024-07-11 US disclosed
US-12030985-B2 Poly(amine-co-ester) polymers and polyplexes with modified end groups and methods of use thereof YALE UNIVERSITY (US) 2024-07-09 US disclosed
US-12030985-B2 Poly(amine-co-ester) polymers and polyplexes with modified end groups and methods of use thereof YALE UNIVERSITY (US) 2024-07-09 US disclosed
EP-4393921-A1 NALIDINONE COMPOUND AS FGFR4 INHIBITOR AND USE THEREOF Wenzhou Medical University (CN) 2024-07-03 EP disclosed
US-12024486-B2 Lipocationic dendrimers and uses thereof THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2024-07-02 US disclosed
US-20240025848-A1 LIPOCATIONIC DENDRIMERS AND USES THEREOF THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2024-01-25 US disclosed
EP-4309674-A1 IONIZABLE CATIONIC LIPID ANALOGUE MATERIAL AND USE THEREOF AS DRUG DELIVERY CARRIER Guangzhou Lide Biomedicine Technology Co., Ltd. (CN) 2024-01-24 EP disclosed
US-20070043057-A1 Lonidamine analogs THRESHOLD PHARMACEUTICALS, INC. (US) 2007-02-22 US disclosed
US-20070037834-A1 Anti-inflammatory; cellular infiltration inhibition modulating activity on thymus and activation-regulated chemokine and macrophage-derived chemokine functions; inhibitory activities against binding of TARC and MDC to T cells; allergic disease, autoimmune disease, transplant, graft rejection KYOWA HAKKO KIRIN CO., LTD. (JP) 2007-02-15 US disclosed
EP-1562944-B1 PYRAZOLOQUINOLINES WITH IMMUNOMODULATING ACTIVITY ACTIVE BIOTECH AB (SE) 2007-02-14 EP disclosed
US-20070032490-A1 N-Phenyl-'(4-pyridyl)-azinyl!amine derivatives as plant protection agents SYNGENTA CROP PROTECTION, INC. 2007-02-08 US disclosed
WO-2005090291-A1 ION CHANNEL MODULATORS WYETH (US) 2005-09-29 WO disclosed
WO-2005058874-A1 5- OR 6-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION TIBOTEC PHARMACEUTICALS LTD. (IE) 2005-06-30 WO disclosed
WO-2004073614-A2 COMBINATION THERAPY FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS COMBINATORX, INCORPORATED (US) 2004-09-02 WO disclosed
US-4992150-A Telomer with alpha-olefin;oil and fuel additive NIPPON OIL CO, LTD. (JP) 1991-02-12 US disclosed
US-3992456-A BY REACTING BUTADIENE WITH WATER IN THE PRESENCE OF A PALLADIUM CATALYST UNION CARBIDE CORPORATION (US) 1976-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269737-A1 7-(Piperazine-1-Ymethyl)-1H-Indole-2-Carboxylic Acid (Phenyl)-Amide Derivatives and Allied Compounds as P38 Map Kinase Inhibitors for the Treatment of Respiratory Diseases MAPKAPK2, MAPKAPK5, MAPK7 GNAI3 368/4885GNAO1 962/4885GNAI1 240/4885
US-20240025848-A1 LIPOCATIONIC DENDRIMERS AND USES THEREOF LIPA, LIPC, TLR9 GNAI3 1032/4885GNAO1 1680/4885GNAI1 990/4885
US-12030985-B2 Poly(amine-co-ester) polymers and polyplexes with modified end groups and methods of use thereof POLM, PARG, PARN GNAI3 3419/4885GNAO1 2580/4885GNAI1 3798/4885
US-12024486-B2 Lipocationic dendrimers and uses thereof LIPA, LIPC, TLR9 GNAI3 1032/4885GNAO1 1680/4885GNAI1 990/4885
US-20070032490-A1 N-Phenyl-'(4-pyridyl)-azinyl!amine derivatives as plant protection agents CYP1A1, NAT1, AKR7A2 GNAI3 2398/4885GNAO1 1670/4885GNAI1 1697/4885
US-20070043057-A1 Lonidamine analogs LONP1, LPXN, QDPR GNAI3 2369/4885GNAO1 1975/4885GNAI1 2095/4885
US-20070037834-A1 Anti-inflammatory; cellular infiltration inhibition modulating activity on thymus and activation-regulated chemokine and macrophage-derived chemokine functions; inhibitory activities against binding of TARC and MDC to T cells; allergic disease, autoimmune disease, transplant, graft rejection CX3CR1, CCL5, CCRL2 GNAI3 2674/4885GNAO1 3166/4885GNAI1 3149/4885
US-20240228493-A1 LRRK2 INHIBITORS AND USES THEREOF LRRK2, PINK1, PARK7 GNAI3 135/4885GNAO1 765/4885GNAI1 132/4885
US-20240239804-A1 FUROINDAZOLE DERIVATIVES AS ANTAGONISTS OR INHIBITORS OF GPR84 GPR84, GPR88, FFAR1 GNAI3 1623/4885GNAO1 1474/4885GNAI1 1211/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.